Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV

Use of tenofovir disoproxil fumarate (TDF) improves patient outcomes in preventing mother-to-child transmission (pMTCT) of the hepatitis B virus (HBV) in mothers with chronic HBV and high viral loads. Given the lack of data for tenofovir alafenamide (TAF) in pMTCT, rates of early viral suppression w...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2021-05, Vol.16 (5), p.e0251552-e0251552
Main Authors: Pan, Calvin Q, Chang, Ting-Tsung, Bae, Si Hyun, Brunetto, Maurizia, Seto, Wai-Kay, Coffin, Carla S, Tan, Susanna K, Mo, Shuyuan, Flaherty, John F, Gaggar, Anuj, Nguyen, Mindie H, Çelen, Mustafa Kemal, Thompson, Alexander, Gane, Edward J
Format: Article
Language:English
Subjects:
Alanine
Alanine transaminase
Analysis
Antigens
Antiretroviral drugs
Antiviral drugs
Biological response modifiers
Biology and life sciences
Care and treatment
Chronic infection
Clinical trials
Complications and side effects
Deoxyribonucleic acid
Disease prevention
DNA
Editing
FDA approval
Health care facilities
Health risks
Hepatitis
Hepatitis B
Hepatitis B surface antigen
Hepatocytes
Hospitals
Infections
Intracellular levels
Kinetics
Liver
Liver diseases
Liver transplantation
Magnetohydrodynamic stability
Medicine
Medicine and health sciences
Patient outcomes
People and Places
Pregnancy
Research and Analysis Methods
Risk analysis
Risk factors
Tenofovir
Vaccines
Viruses
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c625t-6c47447b464ade826ce4467158cfddc130f3c369cd0fc2c76d98df2ee904ab93
cites cdi_FETCH-LOGICAL-c625t-6c47447b464ade826ce4467158cfddc130f3c369cd0fc2c76d98df2ee904ab93
container_end_page e0251552
container_issue 5
container_start_page e0251552
container_title PloS one
container_volume 16
creator Pan, Calvin Q
Chang, Ting-Tsung
Bae, Si Hyun
Brunetto, Maurizia
Seto, Wai-Kay
Coffin, Carla S
Tan, Susanna K
Mo, Shuyuan
Flaherty, John F
Gaggar, Anuj
Nguyen, Mindie H
Çelen, Mustafa Kemal
Thompson, Alexander
Gane, Edward J
description Use of tenofovir disoproxil fumarate (TDF) improves patient outcomes in preventing mother-to-child transmission (pMTCT) of the hepatitis B virus (HBV) in mothers with chronic HBV and high viral loads. Given the lack of data for tenofovir alafenamide (TAF) in pMTCT, rates of early viral suppression with TAF and TDF were evaluated in women of childbearing potential (WOCBP) participating in 2 randomized, double-blind, Phase 3 studies in chronic HBV. In a patient subset meeting WOCBP criteria and with baseline HBV DNA >200,000 IU/mL, rates of viral suppression with TAF or TDF in achieving the target of HBV DNA
doi_str_mv 10.1371/journal.pone.0251552
format article
fullrecord <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2526806680</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A661690309</galeid><doaj_id>oai_doaj_org_article_7c9eee4d9c294440a763ea36e111adf4</doaj_id><sourcerecordid>A661690309</sourcerecordid><originalsourceid>FETCH-LOGICAL-c625t-6c47447b464ade826ce4467158cfddc130f3c369cd0fc2c76d98df2ee904ab93</originalsourceid><addsrcrecordid>eNqFktFqFDEUhgdRbK2-gWhAEL3YmkwymcmNsBa1hUJBS29DNjmzm2022SaZbX0KX9lsd1t2RfAiJOR8-U_-n1NVrwk-JrQln-ZhiF6542XwcIzrhjRN_aQ6JILWI15j-nTnfFC9SGmOcUM7zp9XB5SKjmHaHVa_xz7blY3KoWvrIVudUOhRBh_6UO6RcqoHrxbWAFLe7FSMTWEZw511qB8WKqoMKKwgopqhW4DrhKxHt2EBfq2oZ9aZCaho_RQtQ5HJtjS9tXlWajF4q9Hpl6uX1bNeuQSvtvtRdfnt6-XJ6ej84vvZyfh8pHnd5BHXrGWsnTDOlIGu5hoY4y1pOt0bownFPdWUC21wr2vdciM609cAAjM1EfSoeruRXbqQ5DbKJOum5h3mZRXibEOYoOZyGW1x-EsGZeX9RYhTqWKJy4FstQAAZoSuBWMMq5ZTUJQDIUSZnhWtz9tuw2QBRhfvJfA90f2KtzM5DSvZEVK8rQU-bAViuBkgZbmwSYNzykMY7v_dCcKx6Ar67i_03-4-bqipKgas18FnuMtTNaQkz37-kGPOCReYYvEf9uJqn32_w85AuTxLwQ3ZBp_2QbYBdQwpRegf0yBYruf74dtyPd9yO9_l2ZvdJB8fPQw0_QORBfna</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2526806680</pqid></control><display><type>article</type><title>Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Pan, Calvin Q ; Chang, Ting-Tsung ; Bae, Si Hyun ; Brunetto, Maurizia ; Seto, Wai-Kay ; Coffin, Carla S ; Tan, Susanna K ; Mo, Shuyuan ; Flaherty, John F ; Gaggar, Anuj ; Nguyen, Mindie H ; Çelen, Mustafa Kemal ; Thompson, Alexander ; Gane, Edward J</creator><creatorcontrib>Pan, Calvin Q ; Chang, Ting-Tsung ; Bae, Si Hyun ; Brunetto, Maurizia ; Seto, Wai-Kay ; Coffin, Carla S ; Tan, Susanna K ; Mo, Shuyuan ; Flaherty, John F ; Gaggar, Anuj ; Nguyen, Mindie H ; Çelen, Mustafa Kemal ; Thompson, Alexander ; Gane, Edward J</creatorcontrib><description>Use of tenofovir disoproxil fumarate (TDF) improves patient outcomes in preventing mother-to-child transmission (pMTCT) of the hepatitis B virus (HBV) in mothers with chronic HBV and high viral loads. Given the lack of data for tenofovir alafenamide (TAF) in pMTCT, rates of early viral suppression with TAF and TDF were evaluated in women of childbearing potential (WOCBP) participating in 2 randomized, double-blind, Phase 3 studies in chronic HBV. In a patient subset meeting WOCBP criteria and with baseline HBV DNA &gt;200,000 IU/mL, rates of viral suppression with TAF or TDF in achieving the target of HBV DNA &lt;200,000 IU/mL at weeks 12 and 24 were assessed. Multivariate logistic regression was used to identify factors predictive of failure to suppress HBV DNA to the target level. In 275 of 1298 (21%) patients meeting WOCBP criteria with high viral load, 93% and 96% had HBV DNA &lt;200,000 IU/mL at weeks 12 and 24, respectively. Results for TAF (n = 194) vs TDF (n = 81) treatment were similar at weeks 12 and 24 (94% vs. 90% and 97% vs. 93%), respectively. High baseline HBV DNA level, genotype D infection, and prior interferon (week 24 only) were predictive of failure to achieve the target level. Both treatments were well tolerated with TAF showing less impact on renal and bone parameters. In WOCBP with high VL, no differences were found between TAF and TDF in reducing HBV DNA to levels associated with lower transmission risk. These data support ongoing studies of TAF for pMTCT.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0251552</identifier><identifier>PMID: 33984038</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Alanine ; Alanine transaminase ; Analysis ; Antigens ; Antiretroviral drugs ; Antiviral drugs ; Biological response modifiers ; Biology and life sciences ; Care and treatment ; Chronic infection ; Clinical trials ; Complications and side effects ; Deoxyribonucleic acid ; Disease prevention ; DNA ; Editing ; FDA approval ; Health care facilities ; Health risks ; Hepatitis ; Hepatitis B ; Hepatitis B surface antigen ; Hepatocytes ; Hospitals ; Infections ; Intracellular levels ; Kinetics ; Liver ; Liver diseases ; Liver transplantation ; Magnetohydrodynamic stability ; Medicine ; Medicine and health sciences ; Patient outcomes ; People and Places ; Pregnancy ; Research and Analysis Methods ; Risk analysis ; Risk factors ; Tenofovir ; Vaccines ; Viruses ; Womens health</subject><ispartof>PloS one, 2021-05, Vol.16 (5), p.e0251552-e0251552</ispartof><rights>COPYRIGHT 2021 Public Library of Science</rights><rights>2021 Pan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 Pan et al 2021 Pan et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c625t-6c47447b464ade826ce4467158cfddc130f3c369cd0fc2c76d98df2ee904ab93</citedby><cites>FETCH-LOGICAL-c625t-6c47447b464ade826ce4467158cfddc130f3c369cd0fc2c76d98df2ee904ab93</cites><orcidid>0000-0002-3723-6688</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2526806680/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2526806680?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33984038$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pan, Calvin Q</creatorcontrib><creatorcontrib>Chang, Ting-Tsung</creatorcontrib><creatorcontrib>Bae, Si Hyun</creatorcontrib><creatorcontrib>Brunetto, Maurizia</creatorcontrib><creatorcontrib>Seto, Wai-Kay</creatorcontrib><creatorcontrib>Coffin, Carla S</creatorcontrib><creatorcontrib>Tan, Susanna K</creatorcontrib><creatorcontrib>Mo, Shuyuan</creatorcontrib><creatorcontrib>Flaherty, John F</creatorcontrib><creatorcontrib>Gaggar, Anuj</creatorcontrib><creatorcontrib>Nguyen, Mindie H</creatorcontrib><creatorcontrib>Çelen, Mustafa Kemal</creatorcontrib><creatorcontrib>Thompson, Alexander</creatorcontrib><creatorcontrib>Gane, Edward J</creatorcontrib><title>Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Use of tenofovir disoproxil fumarate (TDF) improves patient outcomes in preventing mother-to-child transmission (pMTCT) of the hepatitis B virus (HBV) in mothers with chronic HBV and high viral loads. Given the lack of data for tenofovir alafenamide (TAF) in pMTCT, rates of early viral suppression with TAF and TDF were evaluated in women of childbearing potential (WOCBP) participating in 2 randomized, double-blind, Phase 3 studies in chronic HBV. In a patient subset meeting WOCBP criteria and with baseline HBV DNA &gt;200,000 IU/mL, rates of viral suppression with TAF or TDF in achieving the target of HBV DNA &lt;200,000 IU/mL at weeks 12 and 24 were assessed. Multivariate logistic regression was used to identify factors predictive of failure to suppress HBV DNA to the target level. In 275 of 1298 (21%) patients meeting WOCBP criteria with high viral load, 93% and 96% had HBV DNA &lt;200,000 IU/mL at weeks 12 and 24, respectively. Results for TAF (n = 194) vs TDF (n = 81) treatment were similar at weeks 12 and 24 (94% vs. 90% and 97% vs. 93%), respectively. High baseline HBV DNA level, genotype D infection, and prior interferon (week 24 only) were predictive of failure to achieve the target level. Both treatments were well tolerated with TAF showing less impact on renal and bone parameters. In WOCBP with high VL, no differences were found between TAF and TDF in reducing HBV DNA to levels associated with lower transmission risk. These data support ongoing studies of TAF for pMTCT.</description><subject>Alanine</subject><subject>Alanine transaminase</subject><subject>Analysis</subject><subject>Antigens</subject><subject>Antiretroviral drugs</subject><subject>Antiviral drugs</subject><subject>Biological response modifiers</subject><subject>Biology and life sciences</subject><subject>Care and treatment</subject><subject>Chronic infection</subject><subject>Clinical trials</subject><subject>Complications and side effects</subject><subject>Deoxyribonucleic acid</subject><subject>Disease prevention</subject><subject>DNA</subject><subject>Editing</subject><subject>FDA approval</subject><subject>Health care facilities</subject><subject>Health risks</subject><subject>Hepatitis</subject><subject>Hepatitis B</subject><subject>Hepatitis B surface antigen</subject><subject>Hepatocytes</subject><subject>Hospitals</subject><subject>Infections</subject><subject>Intracellular levels</subject><subject>Kinetics</subject><subject>Liver</subject><subject>Liver diseases</subject><subject>Liver transplantation</subject><subject>Magnetohydrodynamic stability</subject><subject>Medicine</subject><subject>Medicine and health sciences</subject><subject>Patient outcomes</subject><subject>People and Places</subject><subject>Pregnancy</subject><subject>Research and Analysis Methods</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>Tenofovir</subject><subject>Vaccines</subject><subject>Viruses</subject><subject>Womens health</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqFktFqFDEUhgdRbK2-gWhAEL3YmkwymcmNsBa1hUJBS29DNjmzm2022SaZbX0KX9lsd1t2RfAiJOR8-U_-n1NVrwk-JrQln-ZhiF6542XwcIzrhjRN_aQ6JILWI15j-nTnfFC9SGmOcUM7zp9XB5SKjmHaHVa_xz7blY3KoWvrIVudUOhRBh_6UO6RcqoHrxbWAFLe7FSMTWEZw511qB8WKqoMKKwgopqhW4DrhKxHt2EBfq2oZ9aZCaho_RQtQ5HJtjS9tXlWajF4q9Hpl6uX1bNeuQSvtvtRdfnt6-XJ6ej84vvZyfh8pHnd5BHXrGWsnTDOlIGu5hoY4y1pOt0bownFPdWUC21wr2vdciM609cAAjM1EfSoeruRXbqQ5DbKJOum5h3mZRXibEOYoOZyGW1x-EsGZeX9RYhTqWKJy4FstQAAZoSuBWMMq5ZTUJQDIUSZnhWtz9tuw2QBRhfvJfA90f2KtzM5DSvZEVK8rQU-bAViuBkgZbmwSYNzykMY7v_dCcKx6Ar67i_03-4-bqipKgas18FnuMtTNaQkz37-kGPOCReYYvEf9uJqn32_w85AuTxLwQ3ZBp_2QbYBdQwpRegf0yBYruf74dtyPd9yO9_l2ZvdJB8fPQw0_QORBfna</recordid><startdate>20210513</startdate><enddate>20210513</enddate><creator>Pan, Calvin Q</creator><creator>Chang, Ting-Tsung</creator><creator>Bae, Si Hyun</creator><creator>Brunetto, Maurizia</creator><creator>Seto, Wai-Kay</creator><creator>Coffin, Carla S</creator><creator>Tan, Susanna K</creator><creator>Mo, Shuyuan</creator><creator>Flaherty, John F</creator><creator>Gaggar, Anuj</creator><creator>Nguyen, Mindie H</creator><creator>Çelen, Mustafa Kemal</creator><creator>Thompson, Alexander</creator><creator>Gane, Edward J</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-3723-6688</orcidid></search><sort><creationdate>20210513</creationdate><title>Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV</title><author>Pan, Calvin Q ; Chang, Ting-Tsung ; Bae, Si Hyun ; Brunetto, Maurizia ; Seto, Wai-Kay ; Coffin, Carla S ; Tan, Susanna K ; Mo, Shuyuan ; Flaherty, John F ; Gaggar, Anuj ; Nguyen, Mindie H ; Çelen, Mustafa Kemal ; Thompson, Alexander ; Gane, Edward J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c625t-6c47447b464ade826ce4467158cfddc130f3c369cd0fc2c76d98df2ee904ab93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Alanine</topic><topic>Alanine transaminase</topic><topic>Analysis</topic><topic>Antigens</topic><topic>Antiretroviral drugs</topic><topic>Antiviral drugs</topic><topic>Biological response modifiers</topic><topic>Biology and life sciences</topic><topic>Care and treatment</topic><topic>Chronic infection</topic><topic>Clinical trials</topic><topic>Complications and side effects</topic><topic>Deoxyribonucleic acid</topic><topic>Disease prevention</topic><topic>DNA</topic><topic>Editing</topic><topic>FDA approval</topic><topic>Health care facilities</topic><topic>Health risks</topic><topic>Hepatitis</topic><topic>Hepatitis B</topic><topic>Hepatitis B surface antigen</topic><topic>Hepatocytes</topic><topic>Hospitals</topic><topic>Infections</topic><topic>Intracellular levels</topic><topic>Kinetics</topic><topic>Liver</topic><topic>Liver diseases</topic><topic>Liver transplantation</topic><topic>Magnetohydrodynamic stability</topic><topic>Medicine</topic><topic>Medicine and health sciences</topic><topic>Patient outcomes</topic><topic>People and Places</topic><topic>Pregnancy</topic><topic>Research and Analysis Methods</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>Tenofovir</topic><topic>Vaccines</topic><topic>Viruses</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pan, Calvin Q</creatorcontrib><creatorcontrib>Chang, Ting-Tsung</creatorcontrib><creatorcontrib>Bae, Si Hyun</creatorcontrib><creatorcontrib>Brunetto, Maurizia</creatorcontrib><creatorcontrib>Seto, Wai-Kay</creatorcontrib><creatorcontrib>Coffin, Carla S</creatorcontrib><creatorcontrib>Tan, Susanna K</creatorcontrib><creatorcontrib>Mo, Shuyuan</creatorcontrib><creatorcontrib>Flaherty, John F</creatorcontrib><creatorcontrib>Gaggar, Anuj</creatorcontrib><creatorcontrib>Nguyen, Mindie H</creatorcontrib><creatorcontrib>Çelen, Mustafa Kemal</creatorcontrib><creatorcontrib>Thompson, Alexander</creatorcontrib><creatorcontrib>Gane, Edward J</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological &amp; Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Hospital Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>Agricultural &amp; Environmental Science Collection (subscription)</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central - New (Subscription)</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Meteorological &amp; Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>Biological Sciences</collection><collection>Agriculture Science Database</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest Health &amp; Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health &amp; Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied &amp; Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pan, Calvin Q</au><au>Chang, Ting-Tsung</au><au>Bae, Si Hyun</au><au>Brunetto, Maurizia</au><au>Seto, Wai-Kay</au><au>Coffin, Carla S</au><au>Tan, Susanna K</au><au>Mo, Shuyuan</au><au>Flaherty, John F</au><au>Gaggar, Anuj</au><au>Nguyen, Mindie H</au><au>Çelen, Mustafa Kemal</au><au>Thompson, Alexander</au><au>Gane, Edward J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2021-05-13</date><risdate>2021</risdate><volume>16</volume><issue>5</issue><spage>e0251552</spage><epage>e0251552</epage><pages>e0251552-e0251552</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Use of tenofovir disoproxil fumarate (TDF) improves patient outcomes in preventing mother-to-child transmission (pMTCT) of the hepatitis B virus (HBV) in mothers with chronic HBV and high viral loads. Given the lack of data for tenofovir alafenamide (TAF) in pMTCT, rates of early viral suppression with TAF and TDF were evaluated in women of childbearing potential (WOCBP) participating in 2 randomized, double-blind, Phase 3 studies in chronic HBV. In a patient subset meeting WOCBP criteria and with baseline HBV DNA &gt;200,000 IU/mL, rates of viral suppression with TAF or TDF in achieving the target of HBV DNA &lt;200,000 IU/mL at weeks 12 and 24 were assessed. Multivariate logistic regression was used to identify factors predictive of failure to suppress HBV DNA to the target level. In 275 of 1298 (21%) patients meeting WOCBP criteria with high viral load, 93% and 96% had HBV DNA &lt;200,000 IU/mL at weeks 12 and 24, respectively. Results for TAF (n = 194) vs TDF (n = 81) treatment were similar at weeks 12 and 24 (94% vs. 90% and 97% vs. 93%), respectively. High baseline HBV DNA level, genotype D infection, and prior interferon (week 24 only) were predictive of failure to achieve the target level. Both treatments were well tolerated with TAF showing less impact on renal and bone parameters. In WOCBP with high VL, no differences were found between TAF and TDF in reducing HBV DNA to levels associated with lower transmission risk. These data support ongoing studies of TAF for pMTCT.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>33984038</pmid><doi>10.1371/journal.pone.0251552</doi><tpages>e0251552</tpages><orcidid>https://orcid.org/0000-0002-3723-6688</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1932-6203
ispartof PloS one, 2021-05, Vol.16 (5), p.e0251552-e0251552
issn 1932-6203
1932-6203
language eng
recordid cdi_plos_journals_2526806680
source Publicly Available Content Database; PubMed Central
subjects Alanine
Alanine transaminase
Analysis
Antigens
Antiretroviral drugs
Antiviral drugs
Biological response modifiers
Biology and life sciences
Care and treatment
Chronic infection
Clinical trials
Complications and side effects
Deoxyribonucleic acid
Disease prevention
DNA
Editing
FDA approval
Health care facilities
Health risks
Hepatitis
Hepatitis B
Hepatitis B surface antigen
Hepatocytes
Hospitals
Infections
Intracellular levels
Kinetics
Liver
Liver diseases
Liver transplantation
Magnetohydrodynamic stability
Medicine
Medicine and health sciences
Patient outcomes
People and Places
Pregnancy
Research and Analysis Methods
Risk analysis
Risk factors
Tenofovir
Vaccines
Viruses
Womens health
title Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-03-09T17%3A34%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antiviral%20kinetics%20of%20tenofovir%20alafenamide%20and%20tenofovir%20disoproxil%20fumarate%20over%2024%20weeks%20in%20women%20of%20childbearing%20potential%20with%20chronic%20HBV&rft.jtitle=PloS%20one&rft.au=Pan,%20Calvin%20Q&rft.date=2021-05-13&rft.volume=16&rft.issue=5&rft.spage=e0251552&rft.epage=e0251552&rft.pages=e0251552-e0251552&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0251552&rft_dat=%3Cgale_plos_%3EA661690309%3C/gale_plos_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c625t-6c47447b464ade826ce4467158cfddc130f3c369cd0fc2c76d98df2ee904ab93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2526806680&rft_id=info:pmid/33984038&rft_galeid=A661690309&rfr_iscdi=true